Results 181 to 190 of about 28,958 (244)
Early Anticoagulation in Acute Ischemic Stroke With Atrial Fibrillation. [PDF]
J StrokePark HK, Koga M, Hong KS.
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Idarucizumab for Dabigatran Reversal
New England Journal of Medicine, 2015Specific reversal agents for non-vitamin K antagonist oral anticoagulants are lacking. Idarucizumab, an antibody fragment, was developed to reverse the anticoagulant effects of dabigatran.We undertook this prospective cohort study to determine the safety of 5 g of intravenous idarucizumab and its capacity to reverse the anticoagulant effects of ...
Pollack Jr, C.V. +17 more
openaire +4 more sources
Removal of Dabigatran by Hemodialysis
American Journal of Kidney Diseases, 2013Dabigatran is a newly available oral direct thrombin inhibitor approved for anticoagulation therapy to prevent strokes in patients with nonvalvular atrial fibrillation. Unlike warfarin, dabigatran's observed therapeutic window and minimal drug-to-drug interaction suggest that invasive laboratory testing and dose adjustment is not necessary.
William E Dager
exaly +3 more sources
Annals of Internal Medicine, 2022
BACKGROUND Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.
W. Lau +12 more
semanticscholar +1 more source
BACKGROUND Current guidelines recommend using direct oral anticoagulants (DOACs) over warfarin in patients with atrial fibrillation (AF), but head-to-head trial data do not exist to guide the choice of DOAC.
W. Lau +12 more
semanticscholar +1 more source
The Lancet Haematology, 2020
BACKGROUND Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care in children with venous thromboembolism.
J. Halton +18 more
semanticscholar +1 more source
BACKGROUND Dabigatran etexilate is a direct oral anticoagulant with potential to overcome the limitations of standard of care in children with venous thromboembolism.
J. Halton +18 more
semanticscholar +1 more source
BMJ, 2014
Doctors and patients must tread carefully through emerging risks Options for stroke prevention in high risk non-valvular atrial fibrillation have recently broadened with the addition of new oral anticoagulants as an alternative to warfarin, the traditional and effective treatment.
Blake, Charlton, Rita, Redberg
openaire +2 more sources
Doctors and patients must tread carefully through emerging risks Options for stroke prevention in high risk non-valvular atrial fibrillation have recently broadened with the addition of new oral anticoagulants as an alternative to warfarin, the traditional and effective treatment.
Blake, Charlton, Rita, Redberg
openaire +2 more sources
2023
Abstract Dabigatran is a direct oral anticoagulant that acts through specific and reversible inhibition of thrombin. It has been developed as a fixed-dose, modern alternative to vitamin K antagonists such as warfarin. Dabigatran does not require frequent blood testing or dose adjustments.
Alexander P. Benz, Stefan H. Hohnloser
openaire +1 more source
Abstract Dabigatran is a direct oral anticoagulant that acts through specific and reversible inhibition of thrombin. It has been developed as a fixed-dose, modern alternative to vitamin K antagonists such as warfarin. Dabigatran does not require frequent blood testing or dose adjustments.
Alexander P. Benz, Stefan H. Hohnloser
openaire +1 more source
International Journal of Stroke, 2020
Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for ...
P. Kermer +72 more
semanticscholar +1 more source
Background Idarucizumab is a monoclonal antibody fragment with high affinity for dabigatran reversing its anticoagulant effects within minutes. Thereby, patients with acute ischemic stroke who are on dabigatran treatment may become eligible for ...
P. Kermer +72 more
semanticscholar +1 more source